Sutro Biopharma, Inc.
STRO
$7.30
-$0.72-8.95%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 105.65M | 104.47M | 66.43M | 62.04M | 160.96M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 105.65M | 104.47M | 66.43M | 62.04M | 160.96M |
| Cost of Revenue | -88.04M | -65.79M | -42.09M | -41.20M | 12.47M |
| Gross Profit | 193.69M | 170.26M | 108.53M | 103.24M | 148.48M |
| SG&A Expenses | 41.39M | 46.98M | 49.01M | 48.45M | 56.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 242.20M | 270.04M | 295.77M | 300.50M | 291.00M |
| Operating Income | -136.55M | -165.57M | -229.33M | -238.45M | -130.04M |
| Income Before Tax | -214.43M | -206.36M | -242.85M | -225.10M | -108.14M |
| Income Tax Expenses | 2.34M | 2.34M | 2.36M | 2.36M | 15.82M |
| Earnings from Continuing Operations | -216.77 | -208.70 | -245.22 | -227.46 | -123.95 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -216.77M | -208.70M | -245.22M | -227.46M | -123.95M |
| EBIT | -136.55M | -165.57M | -229.33M | -238.45M | -130.04M |
| EBITDA | -128.99M | -158.10M | -221.98M | -231.24M | -122.96M |
| EPS Basic | -25.98 | -25.23 | -29.78 | -30.11 | -16.24 |
| Normalized Basic EPS | -12.41 | -14.45 | -19.03 | -21.19 | -11.88 |
| EPS Diluted | -25.98 | -25.23 | -29.78 | -30.11 | -16.24 |
| Normalized Diluted EPS | -12.41 | -14.45 | -19.03 | -21.19 | -11.88 |
| Average Basic Shares Outstanding | 33.51M | 33.22M | 32.89M | 30.72M | 28.57M |
| Average Diluted Shares Outstanding | 33.51M | 33.22M | 32.89M | 30.72M | 28.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |